Keros Therapeutics, Inc. Stock Price, News & Analysis

Keros Therapeutics, a clinical-stage biopharmaceutical company, announced that its President and CEO, Jasbir S. Seehra, Ph.D., will present at the Piper Sandler 33rd Annual Virtual Healthcare Conference. The presentation is available from November 22, 2021, at 10:00 a.m. ET, and will be archived on Keros' investor website for 90 days. Keros focuses on developing novel treatments for hematological and musculoskeletal disorders, with product candidates including KER-050 for cytopenias and KER-047 for anemia due to iron imbalance.

Keros Therapeutics, Inc. (Nasdaq: KROS) presented preclinical data on KER-012 at the AHA 2021 Scientific Sessions, showing its potential to reduce cardiac dysfunction and remodeling in a pulmonary arterial banding mouse model. The compound demonstrated a cardio-protective mechanism without increasing red blood cells or hemoglobin, suggesting it could treat pulmonary arterial hypertension (PAH) effectively. KER-012 aims to inhibit growth factors to promote bone growth and address conditions like osteoporosis. Initial data from a Phase 1 trial is expected in 2022.

Keros Therapeutics, Inc. (Nasdaq: KROS), a clinical-stage biopharmaceutical company, announced that its CEO, Jasbir S. Seehra, Ph.D., will present at the Jefferies Virtual London Healthcare Conference on November 18, starting at 3:00 a.m. ET. The presentation will be accessible via the provided link and will be archived on Keros’ website for 90 days. Keros focuses on developing treatments for hematological and musculoskeletal disorders, with key products including KER-050 for cytopenias, KER-047 for iron imbalance-related anemia, and KER-012 for bone loss disorders.

Keros Therapeutics, Inc. (Nasdaq: KROS) has announced the presentation of results from a preclinical study of KER-012 at the upcoming American Heart Association 2021 Scientific Sessions, scheduled from November 13-15, 2021. KER-012 is designed to inhibit certain ligands that suppress bone growth and is being evaluated for treating conditions like osteogenesis imperfecta, osteoporosis, and pulmonary arterial hypertension (PAH). The abstract indicates the potential of KER-012 to attenuate cardiac pathology in models of right ventricle overload.

Keros Therapeutics, Inc. (KROS) reported a net loss of $20.3 million for Q3 2021, up from $12.0 million in Q3 2020, primarily due to heightened research and development efforts. R&D expenses soared to $14.8 million, reflecting aggressive pipeline advancement. The company is progressing with a Phase 2 trial of KER-050 for myelodysplastic syndromes and has initiated a Phase 1 trial for KER-012. Keros has $221.3 million in cash, expected to support operations through Q4 2023. A clinical data update will be provided at the 63rd ASH Annual Meeting in December.

Keros Therapeutics (Nasdaq: KROS) has announced four abstracts for presentation at the 63rd American Society of Hematology Annual Meeting from December 11-14, 2021. Key highlights include preliminary results from the Phase 2 trial of KER-050 for treating anemia in myelodysplastic syndromes (MDS). The abstracts feature clinical presentations on KER-050's efficacy, along with preclinical data supporting its therapeutic potential for cytopenias. Keros aims to address significant unmet medical needs in hematological disorders with its innovative solutions.

Keros Therapeutics, Inc. (Nasdaq: KROS), presented preclinical results of KER-012 at the ASBMR 2021 Annual Meeting, showcasing its efficacy in preventing bone loss in a rodent pulmonary arterial hypertension (PAH) model. RKER-012 demonstrated significant improvements in bone metrics compared to untreated controls, suggesting its potential for treating secondary osteoporosis related to PAH. KER-012 is designed to promote bone growth by inhibiting transforming growth factor-Beta ligands. The company emphasizes KER-012's therapeutic promise for bone loss disorders.

Keros Therapeutics, Inc. (Nasdaq: KROS), a clinical-stage biopharmaceutical company, announced that CEO Jasbir S. Seehra, Ph.D., will participate in two healthcare conferences. The events include the Morgan Stanley 19th Annual Global Healthcare Conference on September 10 at 11:00 AM ET as a fireside chat, and the H.C. Wainwright 23rd Annual Global Investment Conference on September 13 starting at 7:00 AM ET as a corporate presentation. Both presentations will be accessible online and archived on Keros' investor website for 90 days.

Keros Therapeutics, Inc. (KROS) reported significant progress and financial results for Q2 2021, highlighting advancements in their clinical pipeline. The company announced preliminary results from its Phase 2 trial of KER-050, aimed at treating myelodysplastic syndromes. Financially, Keros posted a net loss of $15.6 million for the quarter, up from $10.8 million in Q2 2020, primarily due to increased R&D and administrative expenses. As of June 30, 2021, Keros held $237.1 million in cash, sufficient to fund operations through Q4 2023.